Xiaolin Wang
EVP, Clinical Development · Revolution Medicines, Inc.
- 2026
- Mar 19, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Xiaolin Wang files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Mark A. Goldsmith - $56.99M in RVMD purchases and sales in the last 12 months
- Margaret A. Horn - $25.81M in RVMD purchases and sales in the last 12 months
- Stephen Michael Kelsey - $21.33M in RVMD purchases and sales in the last 12 months
- Jeff Cislini - $15.27M in RVMD purchases and sales in the last 12 months
- Lorence H. Kim - $14.97M in RVMD purchases and sales in the last 12 months
- Anthony Mancini - $9.79M in RVMD purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Xiaolin Wang?
Xiaolin Wang is a corporate insider, tracked as EVP, Clinical Development of Revolution Medicines, Inc. (RVMD). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Xiaolin Wang last file a Form 4?
The most recent primary Form 4 on record is dated 19 March 2026, one of 2 filings going back to 2026.
Has Xiaolin Wang been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($200K) across all tracked filings.
